--- title: "Avacta Therapeutics Seeks £12.5m to Extend Cash Runway Into Q2 2027" publisher: "Share Talk" author: "sharetalk" published: "2026-10-05T20:11:29+00:00" modified: "2026-10-05T20:11:29+00:00" date: 2026-10-05 canonical: "https://www.share-talk.com/avacta-therapeutics-seeks-12-5m-to-extend-cash-runway-into-q2-2027/" category: "Health" categories: ["Health", "Healthcare", "Pharmaceutical"] tags: ["Abingdon Health", "AffyXell Therapeutics", "antigen", "Avacta Group", "AVCT", "Biotherapeutics", "Chris Yates", "Christina Coughlin", "clinical", "COVID-19", "Cytiva", "Daewoong Pharmaceutical", "diagnostic", "Doncaster", "Europe", "LG Chem Life Sciences", "Michelle Morrow", "Pharma", "radiopharmaceuticals", "saliva test", "SARS-COV-2", "Sengho Jeon", "Share Talk", "South Korea", "therapeutic", "UK", "validation", "York"] image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/10/5d27b6d3-7fea-41f8-9ad1-b66d3859542b.png?fit=1727%2C911&ssl=1" format: "news" language: "en-GB" --- # Avacta Therapeutics Seeks £12.5m to Extend Cash Runway Into Q2 2027 **Published:** October 5, 2026 **Author:** sharetalk **Categories:** Health, Healthcare, Pharmaceutical **Tags:** Abingdon Health, AffyXell Therapeutics, antigen, Avacta Group, AVCT, Biotherapeutics, Chris Yates, Christina Coughlin, clinical, COVID-19, Cytiva, Daewoong Pharmaceutical, diagnostic, Doncaster, Europe, LG Chem Life Sciences, Michelle Morrow, Pharma, radiopharmaceuticals, saliva test, SARS-COV-2, Sengho Jeon, Share Talk, South Korea, therapeutic, UK, validation, York **Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/10/5d27b6d3-7fea-41f8-9ad1-b66d3859542b.png?fit=1727%2C911&ssl=1) --- [Avacta Therapeutics (AIM: AVCT)](https://www.investegate.co.uk/announcement/rns/avacta-group--avct/proposed-fundraise-to-raise-approximately-12-5m/9807440)has launched an accelerated bookbuild and subscription seeking minimum gross proceeds of approximately **£12.5 million**. New shares will be issued at **68p each**, representing a discount of approximately **5.6% to the 72p closing mid-market price on 29 September 2026**, the final trading day before Avacta entered its Capital Access Window. The fundraising is intended to extend Avacta’s existing cash runway from **early Q1 2027 into Q2 2027**, while strengthening the balance sheet during continuing discussions with potential partners for its Next-Generation pre|CISION assets. Approximately **£2.5 million of the proceeds will be used to make the next quarterly convertible bond repayment in cash**, due on 20 October 2026. The remainder will support development of Avacta’s oncology pipeline, including **AVA6103, AVA6000 and the dual-payload AVA6207 programme**, alongside general working capital. The fundraising follows Avacta’s September announcement that it had achieved **clinical proof of mechanism for AVA6103** in the ongoing Phase 1 FOCUS-01 trial. Preliminary data from the first three dose levels showed what the company described as a clean safety profile, including dosing at a payload level approximately **50% above the maximum tolerated dose of conventional exatecan**. Pharmacokinetic data also showed controlled release of exatecan over several days and were reported to align closely with Avacta’s preclinical modelling. Importantly, these results demonstrate **mechanism and early safety characteristics rather than clinical efficacy**. The first efficacy data from the FOCUS-01 study are expected during **H1 2027**, making those results a key future test of whether the tumour selectivity and anti-tumour effects seen preclinically translate into patients. Avacta is also continuing the **Phase 1b expansion cohorts of AVA6000**, while progressing AVA6207, which is designed to release two synergistic payloads from a single FAP-cleavage event. The company expects to disclose the selected AVA6207 payloads and supporting dataset during **Q4 2026**, ahead of IND-enabling work and planning for a Phase 1 study. Four Avacta directors have indicated their intention to subscribe for approximately **£660,000**, representing 969,000 shares at the same 68p issue price. Neither the placing nor subscription is **underwritten**, meaning completion remains dependent on sufficient investor demand through the accelerated bookbuild and subscription process. Avacta shares have remained suspended from normal trading under the **Capital Access Window** since 30 September and are expected to remain paused until the company announces the outcome of the fundraising. For investors, the fundraise addresses an immediate balance-sheet requirement and provides additional time for Avacta to generate clinical data and pursue partnering discussions. However, the financing extends the runway by only several months, while **£2.5 million of the proceeds is earmarked for debt repayment rather than clinical development**. The immediate catalysts are therefore the **final size of the fundraising, the resulting dilution, the Q4 AVA6207 update and first AVA6103 efficacy data in H1 2027**. --- **Original URL:** https://www.share-talk.com/avacta-therapeutics-seeks-12-5m-to-extend-cash-runway-into-q2-2027/ *Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*